Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 January 2015Website:
http://www.salariuspharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 22:47:24 GMTDividend
Analysts recommendations
Institutional Ownership
SLRX Latest News
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation.
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
What type of business is Salarius Pharmaceuticals?
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
What sector is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Healthcare sector
What industry is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Biotechnology industry
What country is Salarius Pharmaceuticals from?
Salarius Pharmaceuticals is headquartered in United States
When did Salarius Pharmaceuticals go public?
Salarius Pharmaceuticals initial public offering (IPO) was on 29 January 2015
What is Salarius Pharmaceuticals website?
https://www.salariuspharma.com
Is Salarius Pharmaceuticals in the S&P 500?
No, Salarius Pharmaceuticals is not included in the S&P 500 index
Is Salarius Pharmaceuticals in the NASDAQ 100?
No, Salarius Pharmaceuticals is not included in the NASDAQ 100 index
Is Salarius Pharmaceuticals in the Dow Jones?
No, Salarius Pharmaceuticals is not included in the Dow Jones index
When does Salarius Pharmaceuticals report earnings?
The next expected earnings date for Salarius Pharmaceuticals is 09 August 2024